Oklo Inc. (OKLO) is closing the gap on its losses, seen in its latest earnings report. George Tsilis says the company's promise of creating small nuclear reactors will be bullish for A.I.

WESTERVILLE, Ohio--(BUSINESS WIRE)--Lancaster Colony Corporation (Nasdaq: LANC) announced today that its Board of Directors has declared a quarterly cash dividend of 95 cents per common share, payable June 30, 2025 to shareholders of record on June 6, 2025. The quarterly cash dividend amount of 95 cents per share maintains the higher level set six months ago, which marked the company's 62nd consecutive year of increased regular cash dividends. Lancaster Colony is one of only 12 U.S. companies w.

NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / WHY: New York, N.Y., May 14, 2025.

NEW YORK, NY / ACCESS Newswire / May 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ:CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the "Class Period"), of the important June 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Avis Budget securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / WHY: New York, N.Y., May 14, 2025.

NEW YORK , May 14, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bitfarms Ltd. (NASDAQ: BITF) between March 21, 2023 and December 9, 2024, both dates inclusive (the "Class Period").

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In The Bancorp To Contact Him Directly To Discuss Their Options

Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt.

European Wax Center, Inc. (NASDAQ:EWCZ ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Bethany Johns - Director of Investor Relations Chris Morris - Chairman & Chief Executive Officer Tom Kim - Chief Financial Officer Conference Call Participants Dana Telsey - Telsey Advisory Group Jonathan Komp - Baird John Heinbockel - Guggenheim Securities Korinne Wolfmeyer - Piper Sandler Kelly Crago - Citigroup Simeon Gutman - Morgan Stanley Scot Ciccarelli - Truist Securities Operator Good morning ladies and gentlemen and thank you for standing by. Welcome to European Wax Center's First Quarter Fiscal 2025 Earnings Call.

Aeva Technologies , a firm founded by former Apple engineers that makes sensors used in factories and self-driving vehicles, on Wednesday said it had sold a 6% stake for $50 million to an unnamed strategic partner that will also handle some of its manufacturing in the future.

Key Points Tarrifs, President Trump's visit to Saudi Arabia and global uncertainty has had a huge impact on tech stocks this week.

After more than a year of struggles and uncertainties, the market for Super Micro Computer NASDAQ: SMCI is ready to rebound, rebound strongly, and continue rallying on into the year's end. The reason is that the accounting issues are behind it, and the news cycle is increasingly positive.

Sony Group Corporation's FY24 results were mixed, with flat operations excluding financial services and declining PS5 sales, but strong profitability in core segments. Tariff risks and weak PS5 outlook weigh on guidance, with management expecting flat operating income and lower net income for the coming year. Imaging & Sensing Solutions remains a bright spot, projected to grow despite currency and tariff headwinds, while gaming faces ongoing challenges.

VTR is likely to gain from rising healthcare expenditures among senior citizens. Accretive investments in the research portfolio and solid balance sheet bode well.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options

Analysts are expecting adjusted earnings of 92 cents a share, up 4% from last year.

John Ransom, Raymond James director of healthcare research, joins 'Power Lunch' to discuss why Ransom has pause on shares of UnitedHealth, why the company withdrew its guidance, and much more.

Innoviz Technologies Ltd (NASDAQ:INVZ ) Q1 2025 Earnings Conference Call May 14, 2025 9:00 AM ET Company Participants Omer Keilaf - Chief Executive Officer Eldar Cegla - Chief Financial Officer Conference Call Participants Mark Delaney - Goldman Sachs Jash Patwa - J.P. Morgan Casey Ryan - WestPark Capital Kevin Garrigan - Rosenblatt Securities Operator Good morning.

An analyst reluctantly downgraded UnitedHealth's stock, as the price plunge and a suspended full-year outlook was just too much to hold a bullish stance.

TG's Q1 earnings fall year over year despite a 14% sales rise, as rising aluminum costs and margin pressures impacted profitability, partly offset by strong PE Films gains.